Comments
The Active Pharmaceutical Ingredients (API) facility of Dr Reddy’s Laboratories in Andhra Pradesh has successfully completed a Pre-Approval Inspection (PAI) and a routine GMP inspection by the US drug regulator.
- Also read: Dr Reddy’s launches CeleHealth Kidz Gummies
“The United States Food & Drug Administration (USFDA) today completed a Pre-Approval Inspection (PAI) and a routine GMP inspection at our API manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh,’‘ Dr Reddy’s informed the BSE.
“The inspection was conducted from July 10-19, 2023. The inspection closed with zero observations and a classification of No Action Indicated (NAI),’‘ the Hyderabad-based company said in a release.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.